Fasenra approved in the US for eosinophilic granulomatosis with ...
WEB4 days ago · AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune-mediated vasculitis that can result in damage to multiple organs, and without treatment, can be fatal. 2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the ...
Severe Eosinophilic Asthma Treatment | FASENRA® …
WEBFASENRA® (benralizumab) is an add-on maintenance treatment for patients 6 and older who are diagnosed with severe eosinophilic asthma.
FASENRA approved in the US for eosinophilic granulomatosis …
WEB4 days ago · FASENRA was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly owned subsidiary of Kyowa Kirin Co., Ltd., Japan. AstraZeneca in Respiratory & Immunology Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
FASENRA approved for treatment of children aged 6 to ... - AstraZeneca US
WEBApr 11, 2024 · AstraZeneca’s FASENRA ® (benralizumab) is now approved by the US Food and Drug Administration (FDA) for add-on maintenance treatment for patients with severe asthma aged 6 to 11 with an eosinophilic phenotype. 1 FASENRA was first approved in 2017 as an add-on maintenance for the treatment of severe eosinophilic asthma (SEA) in patients aged ...
AstraZeneca’s Fasenra meets primary endpoint in Phase III rare ...
WEB2 days ago · AstraZeneca’s Fasenra (benralizumab) met its primary endpoint in the MANDARA trial by demonstrating non-inferiority to the current standard of care, GSK’s Nucala (mepolizumab), in patients ...
FASENRA met the primary endpoint in the MANDARA Phase III …
WEBSep 11, 2023 · FASENRA to three injections per month of mepolizumab. Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who ...
Update on the MESSINA Phase III trial for Fasenra in ... - AstraZeneca
WEBOct 25, 2022 · High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints. Fasenra demonstrated a statistically significant improvement in histological disease remission, but not a change in dysphagia symptoms, compared to placebo, in patients with EoE aged 12 years ...
FASENRA approved in the US for eosinophilic ... - Morningstar
WEB4 days ago · AstraZeneca’s FASENRA® (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). 1 EGPA is a rare, immune ...
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
WEB3 days ago · Fasenra is already approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA). Shares of AstraZeneca have increased 16.6% so far this year compared with the industry’s rise ...
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis ...
WEB2 days ago · AstraZeneca is also investigating Fasenra in additional autoimmune conditions, including chronic obstructive pulmonary disease (COPD). However, the therapy failed to meet primary endpoints in ...
Skip to content